J

Johnson & Johnson

Makes prescription drugs and medical devices

Global Distribution Programs Quality Manager

Full-TimePosted on 10/16/2026Deadline 10/24/26
No salary listed
Senior, Expert
Bachelor's, Master's
São Paulo, State of São Paulo, Brazil+1 moreMore locations: São José dos Campos, Sao Jose dos Campos - State of São Paulo, Brazil
Hybrid
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in engineering, science, pharmacy, business, quality, regulatory compliance, supply chain, or a related discipline is required.
  • At least 8 years of progressive experience in a highly regulated healthcare industry, including relevant experience in distribution, transportation, supplier quality, quality management systems, regulatory compliance, commercial quality, or global program management.
  • Demonstrated knowledge of GxP, Good Distribution Practices, applicable healthcare regulations, Johnson & Johnson Quality Standards, quality management system processes, supplier quality, and regulated distribution operations.
  • Demonstrated experience managing complex global or multi-regional quality programs, governance processes, risk-management activities, technology implementations, and organizational change initiatives.
  • FPX or equivalent project-management training is required.
  • Experience coordinating cross-functional and matrixed teams and influencing business and Quality stakeholders without direct authority.
  • Proficiency in written and spoken English; advanced English is required.
  • Ability to communicate and present effectively to management and build credibility across Quality, Supply Chain, Commercial, Regulatory, Procurement, Technology, and external partners.
  • Strong analytical, financial, risk-management, digital, decision-making, project-management, and problem-solving skills.
  • Demonstrated ability to build consensus, lead change, coach others, resolve conflict, and influence without direct authority.
  • Hands-on operational orientation, accountability for results, sound judgment, and tolerance for ambiguity.
Responsibilities
  • Manage assigned global Quality and Compliance transportation, distribution, technology-implementation, and supply-chain quality programs within established strategies, governance frameworks, annual objectives, and business priorities.
  • Develop and maintain program plans, implementation roadmaps, governance routines, performance measures, resource requirements, and improvement actions.
  • Coordinate evaluation and prioritization of initiatives based on compliance risk, business value, customer impact, strategic alignment, implementation complexity, resource requirements, and expected benefits; prepare recommendations for governance approval.
  • Monitor program and quality-system performance through scorecards, management reviews, governance forums, and stakeholder feedback; communicate progress, risks, dependencies, opportunities, resource needs, and decisions required.
  • Support strategy and portfolio-planning processes with program insights, risk assessments, performance trends, resource estimates, and implementation recommendations.
  • Serve as a global Quality subject-matter resource for transportation and distribution, providing technical guidance and program oversight for logistics operations, transportation strategies, network changes, sourcing activities, new capabilities, technology deployments, and operational improvements.
  • Lead development, implementation, harmonization, and maintenance of global Quality requirements for transportation-lane qualification, route and mode verification, transport qualification, controlled ambient and cold-chain logistics, and distribution network changes, subject to applicable governance and approval requirements.
  • Coordinate transportation and distribution risk assessments across products, markets, modes, lanes, suppliers, and logistics service providers, ensuring appropriate controls, actions, monitoring, and escalation.
  • Oversee investigation, product-impact assessment, escalation, remediation, communication, and trending of significant transportation complaints, product damages, delivery issues, and related quality events.
  • Manage global Quality oversight activities for transportation carriers, logistics service providers, freight forwarders, and assigned distribution partners, ensuring consistent application of supplier qualification, quality agreements, purchasing controls, change notification, audits, investigations, corrective and preventive actions, escalation, and disengagement requirements.
  • Monitor supplier performance through approved quality, compliance, service, audit, complaint, risk, and corrective-and-preventive-action metrics; coordinate business reviews, performance-recovery plans, escalations, and continuous-improvement actions.
  • Partner with Global Supplier Quality, Procurement, Transportation, Commercial Quality, and Enterprise Quality to deploy and sustain the enterprise supplier-quality operating model and provide Quality support for sourcing, supplier transitions, network changes, provider onboarding, and contract renewals.
  • Ensure applicable quality management system processes are effectively integrated into assigned transportation, distribution, supplier-quality, technology, and improvement programs, including document management, change control, nonconformance, investigation, corrective and preventive actions, validation, audit, training, metrics, and regulated system requirements.
  • Coordinate required documentation, approvals, system access, periodic reviews, reporting, and effectiveness assessments for assigned programs.
  • Monitor relevant quality-system health and compliance trends, identify recurring or systemic gaps, escalate significant risks, and coordinate corrective and preventive actions.
  • Manage deployment and continuous improvement of Quality and Compliance training requirements supporting assigned distribution programs, including content coordination, implementation, completion monitoring, effectiveness assessment, and reporting.
  • Manage audit and inspection-readiness activities for assigned transportation, distribution, supplier-quality, and quality management system programs in accordance with established enterprise readiness frameworks.
  • Develop and maintain supporting readiness standards, self-assessment tools, review routines, response expectations, escalation pathways, and program reporting.
  • Lead or support preparation and response activities for health authority inspections, Johnson & Johnson Regulatory Compliance audits, notified-body audits, third-party audits, supplier audits, internal audits, compliance reviews, and regulatory inquiries within the assigned scope.
  • Coordinate investigation, remediation, escalation, effectiveness verification, and closure of audit observations, inspection findings, corrective and preventive actions, regulatory commitments, and related actions.
  • Support regulatory interactions in coordination with designated Quality, Regulatory, and business leaders by providing technical information, program records, risk assessments, and response coordination.
  • Develop, implement, and maintain consistent definitions, calculation methods, data-ownership expectations, reporting requirements, and review processes for metrics supporting assigned transportation, supplier-quality, quality management system, compliance-training, audit, quality-event, and improvement programs.
  • Deliver scorecards, trend analyses, and performance insights for Quality Reviews, management reviews, supplier business reviews, and governance forums, highlighting compliance risks, recurring issues, and improvement opportunities.
  • Coordinate data-quality reviews and corrective actions to improve the accuracy, completeness, consistency, and usability of program information.
  • Provide program leadership, coaching, and technical guidance to direct, matrixed, contract, and cross-functional resources supporting assigned global programs.
  • Support capability development through knowledge sharing, coaching, training, mentoring, and assignment-based development opportunities.
  • Define program roles, responsibilities, decision pathways, deliverables, and escalation expectations across global and regional teams and external partners.
  • Lead change-management and adoption activities for assigned processes, systems, technologies, governance practices, and regulatory requirements.
  • Build effective partnerships across internal functions, regions, and external providers to strengthen program alignment and execution.
  • Develop program budget, resource, and investment estimates for assigned global initiatives and provide recommendations through established planning and governance processes.
  • Monitor approved program expenditures, contract-resource utilization, technology costs, benefits realization, and productivity commitments; identify variances and coordinate corrective actions.
  • Support annual planning, forecasting, investment prioritization, and resource-allocation decisions by providing program requirements, options, risks, and business justification.
  • Manage quality-risk activities for assigned global distribution programs by coordinating risk identification, assessment, prioritization, mitigation, monitoring, communication, and escalation in accordance with enterprise risk-management requirements.
  • Participate in selected industry forums, benchmarking activities, and professional networks as assigned; assess relevant regulatory developments, industry trends, and emerging practices and recommend updates to program requirements and improvement plans.
Desired Qualifications
  • An advanced degree is preferred.
  • Experience supporting health authority inspections, notified-body audits, internal audits, suppliers, logistics service providers, and senior-management reviews is preferred.
  • Business alignment, coaching, collaboration, compliance management, continuous improvement, fact-based decision-making, Good Manufacturing Practices, ISO 9001, process improvement, Quality Control, quality management systems, quality standards, quality validation, regulatory environment, standard operating procedures, tactical thinking, and technical credibility.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.